Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples-Reference-Cited by-同舟云学术

Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples

Published:2024-09-02 Issue: Volume: Page:
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Sugiura Hiroyuki^ORCID,Ishikawa Tatsunori,Kuroi Taiga,Okamoto Sachiyo,Nomura Naho,Masunari Taro,Sezaki Nobuo,Ogawa Seishi,Nannya Yasuhito,Makita Masanori

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12185-024-03841-w.pdf

Reference11 articles.

1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850.

2. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77. https://doi.org/10.1182/blood.2022016867.

3. Aparicio-Perez C, Prados de la Torre E, Sanchez-Garcia J, Martin-Calvo C, Martinez-Losada C, Casano-Sanchez J, et al. Evolving risk classifications in AML in a real-life scenario: after changes upon changes, is it more and more adverse? Cancers (Basel). 2023. https://doi.org/10.3390/cancers15051425.

4. Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023;7(9):1899–909. https://doi.org/10.1182/bloodadvances.2022009010.

5. Sargas C, Ayala R, Larrayoz MJ, Chillon MC, Rodriguez-Arboli E, Bilbao C, et al. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J. 2023;13(1):77. https://doi.org/10.1038/s41408-023-00835-5.